Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
出版年份 2023 全文链接
标题
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
作者
关键词
-
出版物
BMC Neurology
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-04-28
DOI
10.1186/s12883-023-03203-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
- (2022) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Migraine therapeutics differentially modulate the CGRP pathway
- (2021) Minoti Bhakta et al. CEPHALALGIA
- Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
- (2021) Uwe Reuter et al. ADVANCES IN THERAPY
- CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis
- (2021) Florian Frank et al. CEPHALALGIA
- Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
- (2021) Lucas Hendrik Overeem et al. CNS DRUGS
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
- (2021) Jessica Ailani et al. HEADACHE
- Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
- (2021) Uwe Reuter et al. CEPHALALGIA
- Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
- (2021) Lucas Hendrik Overeem et al. CEPHALALGIA
- Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
- (2021) Jonathan Gladstone et al. HEADACHE
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
- (2019) William Kielbasa et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class
- (2019) Christian Ziegeler et al. HEADACHE
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
- (2018) HEADACHE
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
- (2013) Stephen D. Silberstein et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Chronic migraine—classification, characteristics and treatment
- (2012) Hans-Christoph Diener et al. Nature Reviews Neurology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started